190 related articles for article (PubMed ID: 35457226)
1. Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer.
Bajbouj K; Qaisar R; Alshura MA; Ibrahim Z; Alebaji MB; Al Ani AW; Janajrah HM; Bilalaga MM; Omara AI; Abou Assaleh RS; Saber-Ayad MM; Elmoselhi AB
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457226
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage.
Mehta M; Griffith J; Panneerselvam J; Babu A; Mani J; Herman T; Ramesh R; Munshi A
Int J Radiat Biol; 2021; 97(8):1109-1120. PubMed ID: 32052681
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
Nakagawa T; Matsushima T; Kawano S; Nakazawa Y; Kato Y; Adachi Y; Abe T; Semba T; Yokoi A; Matsui J; Tsuruoka A; Funahashi Y
Cancer Sci; 2014 Jun; 105(6):723-30. PubMed ID: 24689876
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo anti-angiogenic activities and inhibition of hormone-dependent and -independent breast cancer cells by ceramide methylaminoethylphosphonate.
Chintalapati M; Truax R; Stout R; Portier R; Losso JN
J Agric Food Chem; 2009 Jun; 57(12):5201-10. PubMed ID: 19476359
[TBL] [Abstract][Full Text] [Related]
5. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
6. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y
Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584
[TBL] [Abstract][Full Text] [Related]
7. Angiogenic role of miR-20a in breast cancer.
Luengo-Gil G; Gonzalez-Billalabeitia E; Perez-Henarejos SA; Navarro Manzano E; Chaves-Benito A; Garcia-Martinez E; Garcia-Garre E; Vicente V; Ayala de la Peña F
PLoS One; 2018; 13(4):e0194638. PubMed ID: 29617404
[TBL] [Abstract][Full Text] [Related]
8. The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.
Tonissi F; Lattanzio L; Merlano MC; Infante L; Lo Nigro C; Garrone O
Invest New Drugs; 2015 Aug; 33(4):801-9. PubMed ID: 25947567
[TBL] [Abstract][Full Text] [Related]
9. Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling.
Jiang L; Luan Y; Miao X; Sun C; Li K; Huang Z; Xu D; Zhang M; Kong F; Li N
Br J Cancer; 2017 Aug; 117(5):695-703. PubMed ID: 28697175
[TBL] [Abstract][Full Text] [Related]
10. Effect of Regorafenib on P2X7 Receptor Expression and Different Oncogenic Signaling Pathways in a Human Breast Cancer Cell Line: A Potential of New Insight of the Antitumor Effects of Regorafenib.
Salahuddin MM; Omran GA; Helmy MW; Houssen ME
Curr Issues Mol Biol; 2021 Dec; 43(3):2199-2209. PubMed ID: 34940128
[TBL] [Abstract][Full Text] [Related]
11. Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
Fernand VE; Losso JN; Truax RE; Villar EE; Bwambok DK; Fakayode SO; Lowry M; Warner IM
Chem Biol Interact; 2011 Jul; 192(3):220-32. PubMed ID: 21457705
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic 1-Aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas Inhibit MCF-7 and MDA-MB-231 Human Breast Cancer Cell Lines Through PI3K/Akt and MAPK/Erk Pathways.
Machado VA; Peixoto D; Queiroz MJ; Soares R
J Cell Biochem; 2016 Dec; 117(12):2791-2799. PubMed ID: 27152982
[TBL] [Abstract][Full Text] [Related]
13. A systematical comparison of anti-angiogenesis and anti-cancer efficacy of ramucirumab, apatinib, regorafenib and cabozantinib in zebrafish model.
Wu JQ; Fan RY; Zhang SR; Li CY; Shen LZ; Wei P; He ZH; He MF
Life Sci; 2020 Apr; 247():117402. PubMed ID: 32035930
[TBL] [Abstract][Full Text] [Related]
14. Pomolic acid suppresses HIF1α/VEGF-mediated angiogenesis by targeting p38-MAPK and mTOR signaling cascades.
Park JH; Yoon J; Park B
Phytomedicine; 2016 Dec; 23(14):1716-1726. PubMed ID: 27912873
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
Wilhelm SM; Dumas J; Adnane L; Lynch M; Carter CA; Schütz G; Thierauch KH; Zopf D
Int J Cancer; 2011 Jul; 129(1):245-55. PubMed ID: 21170960
[TBL] [Abstract][Full Text] [Related]
16. Gold nanoparticle-conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2-mediated pathway in breast cancer.
Balakrishnan S; Bhat FA; Raja Singh P; Mukherjee S; Elumalai P; Das S; Patra CR; Arunakaran J
Cell Prolif; 2016 Dec; 49(6):678-697. PubMed ID: 27641938
[TBL] [Abstract][Full Text] [Related]
17. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.
Wang N; Wang ZY; Mo SL; Loo TY; Wang DM; Luo HB; Yang DP; Chen YL; Shen JG; Chen JP
Breast Cancer Res Treat; 2012 Aug; 134(3):943-55. PubMed ID: 22350787
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenesis therapy and gap junction inhibition reduce MDA-MB-231 breast cancer cell invasion and metastasis in vitro and in vivo.
Zibara K; Awada Z; Dib L; El-Saghir J; Al-Ghadban S; Ibrik A; El-Zein N; El-Sabban M
Sci Rep; 2015 Jul; 5():12598. PubMed ID: 26218768
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and caspase-3 gene expression.
Wang B; Wang F; Ding A; Zhao H; Bu X
Clin Transl Oncol; 2020 Sep; 22(9):1491-1498. PubMed ID: 31965535
[TBL] [Abstract][Full Text] [Related]
20. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.
Nakazawa Y; Kawano S; Matsui J; Funahashi Y; Tohyama O; Muto H; Nakagawa T; Matsushima T
Cancer Sci; 2015 Feb; 106(2):201-7. PubMed ID: 25458359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
